|
Name |
Sespendole
|
Molecular Formula | C33H45NO4 | |
IUPAC Name* |
(1S,12S,15S,20R)-7-[(S)-(3,3-dimethyloxiran-2-yl)-hydroxymethyl]-15-hydroxy-1,16,16,20-tetramethyl-8-(3-methylbut-2-enyl)-3-azapentacyclo[10.8.0.02,10.04,9.015,20]icosa-2(10),4(9),5,7-tetraen-17-one
|
|
SMILES |
CC(=CCC1=C(C=CC2=C1C3=C(N2)[C@]4([C@H](C3)CC[C@@]5([C@@]4(CCC(=O)C5(C)C)C)O)C)[C@@H](C6C(O6)(C)C)O)C
|
|
InChI |
InChI=1S/C33H45NO4/c1-18(2)9-10-20-21(26(36)28-30(5,6)38-28)11-12-23-25(20)22-17-19-13-16-33(37)29(3,4)24(35)14-15-31(33,7)32(19,8)27(22)34-23/h9,11-12,19,26,28,34,36-37H,10,13-17H2,1-8H3/t19-,26-,28?,31+,32+,33+/m0/s1
|
|
InChIKey |
QMEIUISJYPRNPF-ZWXFSXOLSA-N
|
|
Synonyms |
Sespendole; SCHEMBL6898712; (1S,12S,15S,20R)-7-[(S)-(3,3-dimethyloxiran-2-yl)-hydroxymethyl]-15-hydroxy-1,16,16,20-tetramethyl-8-(3-methylbut-2-enyl)-3-azapentacyclo[10.8.0.02,10.04,9.015,20]icosa-2(10),4(9),5,7-tetraen-17-one
|
|
CAS | NA | |
PubChem CID | 11598840 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 519.7 | ALogp: | 5.4 |
HBD: | 3 | HBA: | 4 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 85.8 | Aromatic Rings: | 6 |
Heavy Atoms: | 38 | QED Weighted: | 0.329 |
Caco-2 Permeability: | -4.939 | MDCK Permeability: | 0.00001370 |
Pgp-inhibitor: | 0.739 | Pgp-substrate: | 0.95 |
Human Intestinal Absorption (HIA): | 0.177 | 20% Bioavailability (F20%): | 0.975 |
30% Bioavailability (F30%): | 0.982 |
Blood-Brain-Barrier Penetration (BBB): | 0.957 | Plasma Protein Binding (PPB): | 90.00% |
Volume Distribution (VD): | 1.812 | Fu: | 7.46% |
CYP1A2-inhibitor: | 0.084 | CYP1A2-substrate: | 0.904 |
CYP2C19-inhibitor: | 0.511 | CYP2C19-substrate: | 0.878 |
CYP2C9-inhibitor: | 0.655 | CYP2C9-substrate: | 0.794 |
CYP2D6-inhibitor: | 0.286 | CYP2D6-substrate: | 0.595 |
CYP3A4-inhibitor: | 0.707 | CYP3A4-substrate: | 0.886 |
Clearance (CL): | 13.32 | Half-life (T1/2): | 0.101 |
hERG Blockers: | 0.762 | Human Hepatotoxicity (H-HT): | 0.591 |
Drug-inuced Liver Injury (DILI): | 0.047 | AMES Toxicity: | 0.016 |
Rat Oral Acute Toxicity: | 0.971 | Maximum Recommended Daily Dose: | 0.942 |
Skin Sensitization: | 0.095 | Carcinogencity: | 0.962 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.009 |
Respiratory Toxicity: | 0.983 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001923 | 0.530 | D0W2EK | 0.233 | ||||
ENC001967 | 0.507 | D0H2MO | 0.231 | ||||
ENC002013 | 0.412 | D06YFA | 0.228 | ||||
ENC003929 | 0.397 | D04GJN | 0.223 | ||||
ENC005557 | 0.392 | D0W6DG | 0.221 | ||||
ENC003329 | 0.391 | D06IIB | 0.216 | ||||
ENC003931 | 0.383 | D02NSF | 0.215 | ||||
ENC003930 | 0.383 | D0Q0PR | 0.214 | ||||
ENC003787 | 0.379 | D0X3FX | 0.214 | ||||
ENC003875 | 0.377 | D03YVO | 0.214 |